156868-84-7

Basic information

• Product Name: 1-(3-BroMopropyl)-3-fluorobenzene
• Synonyms: 1-(3-BroMopropyl)-3-fluorobenzene;1-(3-Bromopropyl)-3-Fluorobenzene(WX630249)
• CAS NO: 156868-84-7
• Molecular Formula: C₉H₁₀BrF
• Molecular Weight: 217.0781032
• Mol File: 156868-84-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3-BroMopropyl)-3-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-BroMopropyl)-3-fluorobenzene(156868-84-7)
• EPA Substance Registry System: 1-(3-BroMopropyl)-3-fluorobenzene(156868-84-7)

Safety Data

• Hazardous Substances Data: 156868-84-7(Hazardous Substances Data)

Usage

General Description

1-(3-Bromopropyl)-3-fluorobenzene is a chemical compound with the formula C9H9BrF. It is a clear, colorless liquid that is used mainly as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is also used in the production of dyes, polymers, and a variety of other organic chemicals. It is classified as a hazardous material and should be handled with care due to its potential to cause skin and eye irritation, as well as respiratory and central nervous system effects. It is important to follow proper safety protocols when working with 1-(3-Bromopropyl)-3-fluorobenzene to minimize the risk of exposure and adverse health effects.

Upstream product

• 156868-83-6 3-(3-fluorophenyl)propan-1-ol 
• 74325-03-4 methyl (E)-m-fluorocinnamate 
• 425704-52-5 methyl 3-(3-fluorophenyl)propanoate 
• 456-48-4 3-Fluorobenzaldehyde 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 59223-73-3 diethyl 2-(3-fluorobenzyl)malonate 
• 7116-37-2 ethyl 3-(3-fluorophenyl)propanoate 
• 458-45-7 3-(3-fluorophenyl)propionic acid 
• 20595-30-6 3-Fluorocinnamic acid 

Downstream Products

• 156868-61-0 1-<3-(3-fluorophenyl)-propyl>-cyclohexanol 
• 156868-60-9 3-fluoro-α-methylbenzenebutanol 
• 156868-63-2 α-(1,1-dimethylethyl)-3-fluorobenzenebutanol 
• 156868-21-2 3-fluoro-α,α-dimethylbenzenebutanol 
• 86373-35-5 4-[3-(3-Fluoro-phenyl)-propylamino]-benzoic acid ethyl ester 
• 86373-36-6 4-[3-(3-Fluoro-phenyl)-propylamino]-benzoic acid 
• 333782-50-6 methyl (3R,4R)-4-[3-(6-methoxyquinolin-4-yl)propyl]-1-[3-(3-fluorophenyl)propyl]piperidine-3-carboxylate 
• 1206480-88-7 C₁₈H₂₇FN₂O 
• 1093172-54-3 [5-(2-{4-[3-(3-fluorophenyl)propoxy]-3-trifluoromethylphenyl}ethyl)-2,2-dimethyl-1,3-dioxan-5-yl]carbamic acid t-butyl ester 
• 1262643-15-1 1-[3-(3-fluoro-phenyl)-propyl]-1H-indole-3-carbaldehyde 
• 1597430-38-0 3-fluorophenylpropyloxyamine hydrochloride 
• 1597430-54-0 C₁₈H₂₂FN₃O₆ 

Relevant articles and documents

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity

The treatment for patients with chronic obstructive pulmonary disease (COPD) usually involves a combination of anti-inflammatory and bronchodilatory drugs. We recently found that mepenzolate bromide (1) and its derivative, 3-(2-hydroxy-2, 2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (5), have both anti-inflammatory and bronchodilatory activities. We chemically modified 5 with a view to obtain derivatives with both anti-inflammatory and longer-lasting bronchodilatory activities. Among the synthesized compounds, (R)-(–)-12 ((R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide) showed the highest affinity in vitro for the human muscarinic M3 receptor (hM3R). Compared to 1 and 5, (R)-(–)-12 exhibited longer-lasting bronchodilatory activity and equivalent anti-inflammatory effect in mice. The long-term intratracheal administration of (R)-(–)-12 suppressed porcine pancreatic elastase-induced pulmonary emphysema in mice, whereas the same procedure with a long-acting muscarinic antagonist used clinically (tiotropium bromide) did not. These results suggest that (R)-(–)-12 might be therapeutically beneficial for use with COPD patients given the improved effects seen against both inflammatory pulmonary emphysema and airflow limitation in this animal model.

SYNTHESIS AND UTILIZATION OF SMALL MOLECULES FOR THE TREATMENT OF INFLAMMATION ASSOCIATED WITH INTERLEUKIN-1 SIGNALING

The invention describes synthetic compounds, methods of preparation and their uses thereof an anti-inflammatory compounds that reduce inflammation associated with interleukin-1signaling.

3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.